Advertisement
YOU ARE HERE: LAT HomeCollectionsRemicade Drug
IN THE NEWS

Remicade Drug

FEATURED ARTICLES
BUSINESS
August 16, 2001 | DENISE GELLENE, TIMES STAFF WRITER
Johnson & Johnson, acting ahead of a regulatory review, Wednesday warned that patients who take its Remicade rheumatoid arthritis drug face an increased risk of tuberculosis. The drug maker said it is adding a "black box" warning to the Remicade label, the strongest possible for prescription drugs. A Food and Drug Administration committee is scheduled to review Remicade's safety record Friday.
ARTICLES BY DATE
BUSINESS
February 19, 2005 | From Bloomberg News
Johnson & Johnson said it completed research that shows its drug Remicade improved symptoms of the skin disease psoriasis in about 80% of patients who took it. The study's results were presented in New Orleans to the American Academy of Dermatology. The company said it planned to ask the Food and Drug Administration to approve Remicade for use on psoriasis. Shares of New Brunswick, N.J.-based Johnson & Johnson rose 8 cents to $65.43 on the New York Stock Exchange.
Advertisement
NATIONAL
August 25, 2004 | From Times Wire Reports
The Food and Drug Administration and manufacturer Centocor are warning doctors that patients receiving the drug Remicade to treat rheumatoid arthritis and Crohn's disease have suffered sometimes fatal blood and central nervous system disorders. The Malvern, Pa.-based company has revised the drug's label.
BUSINESS
February 15, 2005 | From Bloomberg News
U.S. regulators ordered Johnson & Johnson's Centocor unit to stop using a sales brochure for its Remicade rheumatoid arthritis drug because the document overstated the drug's benefits and omitted risks. The Food and Drug Administration said the material "suggests Remicade is safer and more effective than has been demonstrated by substantial evidence," in a letter to the New Brunswick, N.J.-based company posted on the FDA's website.
BUSINESS
February 19, 2005 | From Bloomberg News
Johnson & Johnson said it completed research that shows its drug Remicade improved symptoms of the skin disease psoriasis in about 80% of patients who took it. The study's results were presented in New Orleans to the American Academy of Dermatology. The company said it planned to ask the Food and Drug Administration to approve Remicade for use on psoriasis. Shares of New Brunswick, N.J.-based Johnson & Johnson rose 8 cents to $65.43 on the New York Stock Exchange.
BUSINESS
February 15, 2005 | From Bloomberg News
U.S. regulators ordered Johnson & Johnson's Centocor unit to stop using a sales brochure for its Remicade rheumatoid arthritis drug because the document overstated the drug's benefits and omitted risks. The Food and Drug Administration said the material "suggests Remicade is safer and more effective than has been demonstrated by substantial evidence," in a letter to the New Brunswick, N.J.-based company posted on the FDA's website.
BUSINESS
January 23, 2004 | Denise Gellene, Times Staff Writer
Amgen Inc.'s profit rose 20% in the fourth quarter on higher sales of drugs for anemia and rheumatoid arthritis, the biotechnology company said Thursday. Net income rose to $547 million, or 41 cents a share, from $456 million, or 34 cents, in the year-earlier quarter. Revenue rose 33% to $2.3 billion, driven by Aranesp for anemia and Enbrel for rheumatoid arthritis. Excluding special charges related to its 2002 acquisition of Immunex Corp.
BUSINESS
March 10, 2009 | William Heisel
Big Pharma got bigger on Monday with Merck Co.'s announcement that it would acquire rival Schering-Plough Corp. in a cash-and-stock transaction worth $41.1 billion. And the deal is being made easier by U.S. taxpayers. Faced with tough competition from generics, fewer potential blockbuster drugs in development and the prospect of a government overhaul of the U.S. healthcare system, drug makers are consolidating. In January, the world's largest pharmaceutical company, Pfizer Inc.
BUSINESS
April 14, 2002 | DENISE GELLENE, TIMES STAFF WRITER
By the end of 1998, Jeanne Harrison thought she had lost a 20-year battle with rheumatoid arthritis. Her wrists had fused and her right elbow had locked at a 45-degree angle. She couldn't dress without help from her husband. The medication she took to slow the disease, a powerful chemotherapy drug called methotrexate, left her nauseated and tired. It was painful to walk and to hug her two children. Then she started taking a drug called Enbrel and everything changed.
NATIONAL
August 25, 2004 | From Times Wire Reports
The Food and Drug Administration and manufacturer Centocor are warning doctors that patients receiving the drug Remicade to treat rheumatoid arthritis and Crohn's disease have suffered sometimes fatal blood and central nervous system disorders. The Malvern, Pa.-based company has revised the drug's label.
BUSINESS
August 16, 2001 | DENISE GELLENE, TIMES STAFF WRITER
Johnson & Johnson, acting ahead of a regulatory review, Wednesday warned that patients who take its Remicade rheumatoid arthritis drug face an increased risk of tuberculosis. The drug maker said it is adding a "black box" warning to the Remicade label, the strongest possible for prescription drugs. A Food and Drug Administration committee is scheduled to review Remicade's safety record Friday.
Los Angeles Times Articles
|